BrainsWay
BWAY | NASDAQ
$9.39
-$0.72 (-7.12%)
At close: Nov 16, 2026, 4:00 PM ET
$9.39
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
BrainsWay Company Profile
Company profile explainedCompany Profile
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Key Executives
| Name | Position |
|---|---|
| Hadar Levy | Chief Executive Officer |
| Gilead Moiseyev | Chief Technology Officer |
| Ido Marom | Chief Financial Officer |
| Naomi Rozenfeld | Chief Marketing Officer |
| Abraham Zangen | Co-Founder, Member of Scientific Advisory Board & Director |
| Colleen Hanlon | Vice President of Medical Affairs |
| David Zacut | Co-Founder & Vice-Chairman |
| Dor Hagai | Vice President of Operations |
| Menachem C. Klein | Vice President, General Counsel & Corporate Secretary |
| Michael Cohen | Vice President of US Sales |
| Yiftach Roth | Founder & Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 26, 2026 | 6-K/A | [Amend] Filing |
| Oct 26, 2026 | 6-K | Filing |
| Oct 21, 2026 | 6-K | Filing |
| Oct 19, 2026 | 6-K | Filing |
| Oct 13, 2026 | 6-K | Filing |
| Sep 29, 2026 | 6-K | Filing |
| Sep 08, 2026 | 6-K | Filing |
| Aug 27, 2026 | 6-K | Filing |
| Aug 12, 2026 | 6-K | Filing |
| Aug 12, 2026 | 6-K | Filing |
BrainsWay
| Country | Israel |
| IPO Date | Apr 17, 2019 |
| Industry | Medical - Specialties |
| Sector | Healthcare |
| Employees | 129 |
| CEO | Hadar Levy |
Stock Details
| Ticker Symbol | BWAY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001505065 |
| CUSIP Number | 10501L106 |
| ISIN Number | US10501L1061 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove BWAY